Skip to main content

Table 5 Soluble PRR, renin, and prorenin in plasma and urine distributed by type of anti-hypertensive treatment

From: Sex differences in soluble prorenin receptor in patients with type 2 diabetes

  Control Type 2 diabetes
  No meds ARBs ACEi ARB/ACEi β-blockers Calcium blockers Diuretics
Total participants, n 167 25 13 30 4 19 1 4
Plasma  
  sPRR (ng/mL) 16.6 ± 4.1 17.3 ± 6.4 21.8 ± 9.8* 18.1 ± 4.3 23.3 ± 7.0 20.0 ± 8.6 11.9 22.7 ± 4.1
  Renin activity (ng Ang-I/mL/h) 3.3 ± 0.3 13.2 ± 2.0* 17.1 ± 1.7* 11.8 ± 1.7* 5.4 ± 1.2 10.0 ± 1.7* 21.12 7.5 ± 5.5
Urine         
  sPRR/uCr (ng/mg) 16 ± 1.6 0.95 ± 0.8 0.90 ± 0.8 0.81 ± 0.9 0.40 ± 0.2 1.0 ± 1.4 115 0.91 ± 0.5
  Renin activity (ng Ang-I/mL/h) 26.9 ± 36 102.1 ± 102* 51.46 ± 44* 96.89 ± 105* 221.1 ± 182* 102.2 ± 73* 273.8 50.12 ± 23*
  Prorenin/uCr (ng/g) 142.1 ± 159 270.7 ± 326 346.5 ± 281.8 275.5 ± 236.1 113.0 ± 12.87 357 ± 336* 1075 202 ± 148
Men, n 69 10 5 12 3 11 0 0
Plasma         
  sPRR (ng/mL) 18 ± 4.7 16.3 ± 5.0 17.4 ± 4.8 18.2 ± 4.7 25.4 ± 7.0 17.0 ± 6.2
  Renin activity (ng Ang-I/mL/h) 3.2 ± 3.6 13.2 ± 12* 4.2 (n = 1) 9.3 ± 7.1 4.9 ± 2.8 6.5 ± 3.3
Urine         
  sPRR/uCr (ng/mg) 1.4 ± 1.2 0.78 ± 0.8 0.4 ± 0.5 0.65 ± 0.5 0.36 ± 0.25 0.65 ± 0.5
  Renin activity (ng Ang-I/mL/h) 15 ± 17.6 131.5 ± 1.4* 28.41 (n = 1) 108 ± 107* 308 ± 142* 105.8 ± 52*
  Prorenin/uCr (ng/g) 120 ± 97.2 380 ± 0.4 953.5 (n = 1) 215 ± 156 113 ± 12.9 520.2 ± 388*
Women, n 99 15 8 18 1 8 1 4
Plasma         
  sPRR (ng/mL) 15.5 ± 3.3 17.8 ± 7.3 24.5 ± 11.3* 18.1 ± 4.2 17.2 23.8 ± 10* 12 22.7 ± 4.2
  Renin activity (ng Ang-I/mL/h) 2.8 ± 2.4 13.2 ± 8.0* 18.8 ± 1.9* 13.3 ± 8.4* 6.4 11.1 ± 6.4* 21.12 7.5 ± 9.7
Urine         
  sPRR/uCr (ng/mg) 0.95 ± 0.08 0.86 ± 0.1 1.2 ± 0.1 0.49 ± 0.1 0.53 1.5 ± 0.2 0.11 0.780 ± 0.61
  Renin activity (ng Ang-I/mL/h) 19.5 ± 22 84 ± 68* 54 ± 45 67.6 ± 50* 46 97.6 ± 98* 273 50.1 ± 23
  Prorenin/uCr (ng/g) 99.4 ± 84.7 207 ± 198 260 ± 150 312.3 ± 271* 193.4 ± 180 1075 202 ± 147
  1. Data are expressed as mean ± SD. sPRR soluble prorenin receptor, uCr urine creatinine. *Different from controls; Different from patient with type 2 diabetes: no medication, ACEi, ABRs